Industries · Life science
Long development cycles call for finances with stamina.
In biotech, medtech and pharma, development, funding and regulation stretch over many years. We give management and investors accounts and reporting that hold up all the way, and we work with the advisers who serve the industry.
In life science, years often pass before there is revenue. That puts more demands on the numbers, not fewer.
Who it is for
For biotech and medtech companies in start-up and growth, for companies with development activities in Denmark, and for the consultants, laboratories and suppliers who work for the life science industry.
We know the finances that come before and around the major breakthroughs: capital raising, grants, milestones and a cost base that must be tightly managed.
What we see in the industry.
- Long runwayDevelopment over many years before there is income.
- Development costsShould they be capitalised or expensed, and what does that mean for the accounts?
- Grants and fundingProject accounts and reporting to foundations and programmes.
- InvestorsInvestors who expect consistent key figures and a fixed rhythm.
- Licences and milestonesIncome from licences, partnerships and milestone payments.
- InternationalPartners, subsidiaries and employees in several countries.
What we deliver.
- Accounts and reportingAnnual report and management reporting that stand up to investors and auditors.
- Project accountsMeasurement and reporting of grant-funded projects.
- Budget and runwayScenarios that show how far your capital will go.
- Tax creditCalculation of research and development losses under the Danish tax credit scheme (skattekreditordningen).
- CFO advisoryAn experienced partner for management and the board.
- International structureSubsidiaries, intra-group agreements and reporting across countries.
Science takes the time it takes. The finances must be ready all the way.
How we work.
- ConversationPipeline, funding and plans.
- FoundationAccounts, structure and systems put in order.
- Key figuresWe define the numbers management, the board and investors need to follow.
- ReportingA fixed rhythm for management, investors and grant providers.
- ScalingThe function grows as your company grows.
The ecosystem
We work with those who work for the industry.
We already advise companies that serve the life science industry, and we know the demands the industry places on documentation and precision.
That gives us a realistic picture of what it takes when a new company is to grow in one of the most regulated markets.
Questions.
What is the tax credit scheme?
A scheme under which companies with losses from research and development can, under certain conditions, have the tax value of part of the loss paid out.
Can you prepare project accounts for grant providers?
Yes. We measure and report on grant-funded projects according to each grant provider's requirements.
Do you work with companies without revenue?
Yes. Many life science companies have no revenue in their first years. This is exactly when managing costs and runway matters most.
Do you work with advisers and suppliers to the industry?
Yes. We already advise companies that serve the life science industry, and we know the demands their customers make.
How do we get started?
With a conversation in which we go through your situation and plans.
Related services